Table Info

Table 1.

Most common γδ T cell subsets in mouse and human

	Circulating subsets	Tissue-resident subsets
Mouse	Vγ1.1⁺ Vγ2⁺	Vγ3⁺ (epidermis) Vγ4⁺ (dermis, lung, uterus, adipose, liver) Vγ5⁺ (gut)
Human	Vδ2⁺	Vδ1⁺ (epidermis, dermis, adipose, gut, liver)

Declarations

Acknowledgments

The authors thank Travis Young (TSRI) and Nelson Bruno (TSRI) for their helpful comments on the scope and clarity of the manuscript.

Author contributions

JMM and DAW wrote the manuscript. All authors contributed to the article and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

This work was supported by NIH grants AI144825 and AI154918 (DW). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Nielsen MM, Witherden DA, Havran WL. γδ T cells in homeostasis and host defence of epithelial barrier tissues. Nat Rev Immunol. 2017;17:733–45. [DOI] [PubMed] [PMC]

Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, et al. Regulation of cutaneous malignancy by gammadelta T cells. Science. 2001;294:605–9. [DOI] [PubMed]

Gao Y, Yang W, Pan M, Scully E, Girardi M, Augenlicht LH, et al. Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J Exp Med. 2003;198:433–42. [DOI] [PubMed] [PMC]

Lança T, Costa MF, Gonçalves-Sousa N, Rei M, Grosso AR, Penido C, et al. Protective role of the inflammatory CCR2/CCL2 chemokine pathway through recruitment of type 1 cytotoxic γδ T lymphocytes to tumor beds. J Immunol. 2013;190:6673–80. [DOI] [PubMed]

Silva-Santos B, Mensurado S, Coffelt SB. gamma delta T cells: pleiotropic immune effectors with therapeutic potential in cancer. Nat Rev Cancer. 2019;19:392–404. [DOI] [PubMed]

Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21:938–45. [DOI] [PubMed] [PMC]

Gherardin NA, Waldeck K, Caneborg A, Martelotto LG, Balachander S, Zethoven M, et al. γδ T cells in merkel cell carcinomas have a proinflammatory profile prognostic of patient survival. Cancer Immunol Res. 2021;9:612–23. [DOI] [PubMed]

Wu Y, Kyle-Cezar F, Woolf RT, Naceur-Lombardelli C, Owen J, Biswas D, et al. An innate-like Vδ1⁺ γδ T cell compartment in the human breast is associated with remission in triple-negative breast cancer. Sci Transl Med. 2019;11:eaax9364. [DOI] [PubMed] [PMC]

Foord E, Arruda LCM, Gaballa A, Klynning C, Uhlin M. Characterization of ascites- and tumor-infiltrating γδ T cells reveals distinct repertoires and a beneficial role in ovarian cancer. Sci Transl Med. 2021;13:eabb0192. [DOI] [PubMed]

10.

Imbert C, Olive D. γδ T cells in tumor microenvironment. Adv Exp Med Biol. 2020;1273:91–104. [DOI] [PubMed]

11.

Willcox BE, Willcox CR. γδ TCR ligands: the quest to solve a 500-million-year-old mystery. Nat Immunol. 2019;20:121–8. [DOI] [PubMed]

12.

Silva-Santos B, Serre K, Norell H. γδ T cells in cancer. Nat Rev Immunol. 2015;15:683–91. [DOI] [PubMed]

13.

Thelen F, Witherden DA. Get in touch with dendritic epithelial T cells! Front Immunol. 2020;11:1656. [DOI] [PubMed] [PMC]

14.

Jameson J, Ugarte K, Chen N, Yachi P, Fuchs E, Boismenu R, et al. A role for skin gammadelta T cells in wound repair. Science. 2002;296:747–9. [DOI] [PubMed]

15.

Komori HK, Witherden DA, Kelly R, Sendaydiego K, Jameson JM, Teyton L, et al. Cutting edge: dendritic epidermal γδ T cell ligands are rapidly and locally expressed by keratinocytes following cutaneous wounding. J Immunol. 2012;188:2972–6. [DOI] [PubMed] [PMC]

16.

Sharp LL, Jameson JM, Cauvi G, Havran WL. Dendritic epidermal T cells regulate skin homeostasis through local production of insulin-like growth factor 1. Nat Immunol. 2005;6:73–9. [DOI] [PubMed]

17.

Matsue H, Cruz PD Jr, Bergstresser PR, Takashima A. Profiles of cytokine mRNA expressed by dendritic epidermal T cells in mice. J Invest Dermatol. 1993;101:537–42. [DOI] [PubMed]

18.

Witherden DA, Johnson MD, Havran WL. Coreceptors and their ligands in epithelial γδ T cell biology. Front Immunol. 2018;9:731. [DOI] [PubMed] [PMC]

19.

Baugh R, Khalique H, Seymour LW. Convergent evolution by cancer and viruses in evading the NKG2D immune response. Cancers (Basel). 2020;12:3827. [DOI] [PubMed] [PMC]

20.

Lanier LL. NKG2D receptor and its ligands in host defense. Cancer Immunol Res. 2015;3:575–82. [DOI] [PubMed] [PMC]

21.

Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999;285:727–9. [DOI] [PubMed]

22.

Carena I, Shamshiev A, Donda A, Colonna M, Libero GD. Major histocompatibility complex class I molecules modulate activation threshold and early signaling of T cell antigen receptor-gamma/delta stimulated by nonpeptidic ligands. J Exp Med. 1997;186:1769–74. [DOI] [PubMed] [PMC]

23.

Strid J, Roberts SJ, Filler RB, Lewis JM, Kwong BY, Schpero W, et al. Acute upregulation of an NKG2D ligand promotes rapid reorganization of a local immune compartment with pleiotropic effects on carcinogenesis. Nat Immunol. 2008;9:146–54. [DOI] [PubMed]

24.

Dalessandri T, Crawford G, Hayes M, Castro Seoane R, Strid J. IL-13 from intraepithelial lymphocytes regulates tissue homeostasis and protects against carcinogenesis in the skin. Nat Commun. 2016;7:12080. [DOI] [PubMed] [PMC]

25.

Strid J, Sobolev O, Zafirova B, Polic B, Hayday A. The intraepithelial T cell response to NKG2D-ligands links lymphoid stress surveillance to atopy. Science. 2011;334:1293–7. [DOI] [PubMed] [PMC]

26.

Yoshida S, Mohamed RH, Kajikawa M, Koizumi J, Tanaka M, Fugo K, et al. Involvement of an NKG2D ligand H60c in epidermal dendritic T cell-mediated wound repair. J Immunol. 2012;188:3972–9. [DOI] [PubMed]

27.

Nielsen MM, Dyring-Andersen B, Schmidt JD, Witherden D, Lovato P, Woetmann A, et al. NKG2D-dependent activation of dendritic epidermal T cells in contact hypersensitivity. J Invest Dermatol. 2015;135:1311–9. [DOI] [PubMed] [PMC]

28.

Nitahara A, Shimura H, Ito A, Tomiyama K, Ito M, Kawai K. NKG2D ligation without T cell receptor engagement triggers both cytotoxicity and cytokine production in dendritic epidermal T cells. J Invest Dermatol. 2006;126:1052–8. [DOI] [PubMed]

29.

Ibusuki A, Kawai K, Yoshida S, Uchida Y, Nitahara-Takeuchi A, Kuroki K, et al. NKG2D triggers cytotoxicity in murine epidermal γδ T cells via PI3K-dependent, Syk/ZAP70-independent signaling pathway. J Invest Dermatol. 2014;134:396–404. [DOI] [PubMed]

30.

Wrobel P, Shojaei H, Schittek B, Gieseler F, Wollenberg B, Kalthoff H, et al. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition. Scand J Immunol. 2007;66:320–8. [DOI] [PubMed]

31.

Silva-Santos B, Strid J. Working in “NK mode”: natural killer group 2 member D and natural cytotoxicity receptors in stress-surveillance by γδ T cells. Front Immunol. 2018;9:851. [DOI] [PubMed] [PMC]

32.

Cao G, Wang Q, Li G, Meng Z, Liu H, Tong J, et al. mTOR inhibition potentiates cytotoxicity of Vγ4 γδ T cells via up-regulating NKG2D and TNF-α. J Leukoc Biol. 2016;100:1181–9. [DOI] [PubMed]

33.

Kummer D, Ebnet K. Junctional adhesion molecules (JAMs): the JAM-integrin connection. Cells. 2018;7:25. [DOI] [PubMed] [PMC]

34.

Lauko A, Mu Z, Gutmann DH, Naik UP, Lathia JD. Junctional adhesion molecules in cancer: a paradigm for the diverse functions of cell-cell interactions in tumor progression. Cancer Res. 2020;80:4878–85. [DOI] [PubMed] [PMC]

35.

Luissint AC, Lutz PG, Calderwood DA, Couraud PO, Bourdoulous S. JAM-L-mediated leukocyte adhesion to endothelial cells is regulated in cis by alpha4beta1 integrin activation. J Cell Biol. 2008;183:1159–73. [DOI] [PubMed] [PMC]

36.

Moog-Lutz C, Cavé-Riant F, Guibal FC, Breau MA, Di Gioia Y, Couraud PO, et al. JAML, a novel protein with characteristics of a junctional adhesion molecule, is induced during differentiation of myeloid leukemia cells. Blood. 2003;102:3371–8. [DOI] [PubMed]

37.

Witherden DA, Verdino P, Rieder SE, Garijo O, Mills RE, Teyton L, et al. The junctional adhesion molecule JAML is a costimulatory receptor for epithelial gammadelta T cell activation. Science. 2010;329:1205–10. [DOI] [PubMed] [PMC]

38.

McGraw JM, Thelen F, Hampton EN, Bruno NE, Young TS, Havran WL, et al. JAML promotes CD8 and γδ T cell antitumor immunity and is a novel target for cancer immunotherapy. J Exp Med. 2021;218:e20202644. [DOI] [PubMed] [PMC]

39.

Reeh M, Bockhorn M, Görgens D, Vieth M, Hoffmann T, Simon R, et al. Presence of the coxsackievirus and adenovirus receptor (CAR) in human neoplasms: a multitumour array analysis. Br J Cancer. 2013;109:1848–58. [DOI] [PubMed] [PMC]

40.

Nilchian A, Johansson J, Ghalali A, Asanin ST, Santiago A, Rosencrantz O, et al. CXADR-mediated formation of an AKT inhibitory signalosome at tight junctions controls epithelial-mesenchymal plasticity in breast cancer. Cancer Res. 2019;79:47–60. [DOI] [PubMed]

41.

Anders M, Vieth M, Röcken C, Ebert M, Pross M, Gretschel S, et al. Loss of the coxsackie and adenovirus receptor contributes to gastric cancer progression. Br J Cancer. 2009;100:352–9. [DOI] [PubMed] [PMC]

42.

Witherden DA, Verdino P, Rieder SE, Garijo O, Mills RS, Teyton L, et al. The junctional adhesion molecule JAML is a costimulatory receptor for epithelial gammadelta T cell activation. Science. 2010;329:1205–10. [DOI] [PubMed] [PMC]

43.

Maleki KT, Cornillet M, Björkström NK. Soluble SEMA4D/CD100: a novel immunoregulator in infectious and inflammatory diseases. Clin Immunol. 2016;163:52–9. [DOI] [PubMed]

44.

Shi W, Kumanogoh A, Watanabe C, Uchida J, Wang X, Yasui T, et al. The class IV semaphorin CD100 plays nonredundant roles in the immune system: defective B and T cell activation in CD100-deficient mice. Immunity. 2000;13:633–42. [DOI] [PubMed]

45.

Kumanogoh A, Suzuki K, Ch’ng E, Watanabe C, Marukawa S, Takegahara N, et al. Requirement for the lymphocyte semaphorin, CD100, in the induction of antigen-specific T cells and the maturation of dendritic cells. J Immunol. 2002;169:1175–81. [DOI] [PubMed]

46.

Pan C, Baumgarth N, Parnes JR. CD72-deficient mice reveal nonredundant roles of CD72 in B cell development and activation. Immunity. 1999;11:495–506. [DOI] [PubMed]

47.

Elhabazi A, Delaire S, Bensussan A, Boumsell L, Bismuth G. Biological activity of soluble CD100. I. The extracellular region of CD100 is released from the surface of T lymphocytes by regulated proteolysis. J Immunol. 2001;166:4341–7. [DOI] [PubMed]

48.

Delaire S, Billard C, Tordjman R, Chédotal A, Elhabazi A, Bensussan A, et al. Biological activity of soluble CD100. II. Soluble CD100, similarly to H-SemaIII, inhibits immune cell migration. J Immunol. 2001;166:4348–54. [DOI] [PubMed]

49.

Kruger RP, Aurandt J, Guan KL. Semaphorins command cells to move. Nat Rev Mol Cell Biol. 2005;6:789–800. [DOI] [PubMed]

50.

Witherden DA, Watanabe M, Garijo O, Rieder SE, Sarkisyan G, Cronin SJ, et al. The CD100 receptor interacts with its plexin B2 ligand to regulate epidermal γδ T cell function. Immunity. 2012;37:314–25. [DOI] [PubMed] [PMC]

51.

Meehan TF, Witherden DA, Kim CH, Sendaydiego K, Ye I, Garijo O, et al. Protection against colitis by CD100-dependent modulation of intraepithelial γδ T lymphocyte function. Mucosal Immunol. 2014;7:134–42. [DOI] [PubMed] [PMC]

52.

Zhang C, Xiao C, Dang E, Cao J, Zhu Z, Fu M, et al. CD100-plexin-B2 promotes the inflammation in psoriasis by activating NF-κB and the inflammasome in keratinocytes. J Invest Dermatol. 2018;138:375–83. [DOI] [PubMed]

53.

Tamagnone L, Franzolin G. Targeting semaphorin 4D in cancer: a look from different perspectives. Cancer Res. 2019;79:5146–8. [DOI] [PubMed]

54.

Wang JS, Jing CQ, Shan KS, Chen YZ, Guo XB, Cao ZX, et al. Semaphorin 4D and hypoxia-inducible factor-1α overexpression is related to prognosis in colorectal carcinoma. World J Gastroenterol. 2015;21:2191–8. [DOI] [PubMed] [PMC]

55.

Chen Y, Zhang L, Lv R, Zhang WQ. Overexpression of semaphorin4D indicates poor prognosis and prompts monocyte differentiation toward M2 macrophages in epithelial ovarian cancer. Asian Pac J Cancer Prev. 2013;14:5883–90. [DOI] [PubMed]

56.

Ch’ng E, Tomita Y, Zhang B, He J, Hoshida Y, Qiu Y, et al. Prognostic significance of CD100 expression in soft tissue sarcoma. Cancer. 2007;110:164–72. [DOI] [PubMed]

57.

Liu H, Yang Y, Xiao J, Yang S, Liu Y, Kang W, et al. Semaphorin 4D expression is associated with a poor clinical outcome in cervical cancer patients. Microvasc Res. 2014;93:1–8. [DOI] [PubMed]

58.

Sierra JR, Corso S, Caione L, Cepero V, Conrotto P, Cignetti A, et al. Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. J Exp Med. 2008;205:1673–85. [DOI] [PubMed] [PMC]

59.

Younis RH, Han KL, Webb TJ. Human head and neck squamous cell carcinoma-associated semaphorin 4D induces expansion of myeloid-derived suppressor cells. J Immunol. 2016;196:1419–29. [DOI] [PubMed] [PMC]

60.

Clavijo PE, Friedman J, Robbins Y, Moore EC, Smith E, Zauderer M, et al. Semaphorin4D inhibition improves response to immune-checkpoint blockade via attenuation of MDSC recruitment and function. Cancer Immunol Res. 2019;7:282–91. [DOI] [PubMed] [PMC]

61.

Wang HM, Zhang XH, Ye LQ, Zhang K, Yang NN, Geng S, et al. Insufficient CD100 shedding contributes to suppression of CD8⁺ T-cell activity in non-small cell lung cancer. Immunology. 2020;160:209–19. [DOI] [PubMed] [PMC]

62.

Chitadze G, Oberg HH, Wesch D, Kabelitz D. The ambiguous role of γδ T lymphocytes in antitumor immunity. Trends Immunol. 2017;38:668–78. [DOI] [PubMed]

63.

Bui TM, Wiesolek HL, Sumagin R. ICAM-1: a master regulator of cellular responses in inflammation, injury resolution, and tumorigenesis. J Leukoc Biol. 2020;108:787–99. [DOI] [PubMed] [PMC]

64.

Walling BL, Kim M. LFA-1 in T cell migration and differentiation. Front Immunol. 2018;9:952. [DOI] [PubMed] [PMC]

65.

Perez OD, Mitchell D, Jager GC, South S, Murriel C, McBride J, et al. Leukocyte functional antigen 1 lowers T cell activation thresholds and signaling through cytohesin-1 and Jun-activating binding protein 1. Nat Immunol. 2003;4:1083–92. [DOI] [PubMed]

66.

Goedegebuure PS, Braakman E, Segal DM, Vreugdenhil RJ, Bolhuis RL. Lymphocyte leukocyte function-associated antigen 1 interacting with target cell intercellular adhesion molecule 1 co-activates cytolysis triggered via CD16 or the receptor involved in major histocompatibility antigen-unrestricted lysis. Int Immunol. 1990;2:1213–20. [DOI] [PubMed]

67.

Ensslin AS, Formby B. Comparison of cytolytic and proliferative activities of human gamma delta and alpha beta T cells from peripheral blood against various human tumor cell lines. J Natl Cancer Inst. 1991;83:1564–9. [DOI] [PubMed]

68.

Nelson EL, Kim HT, Mar ND, Goralski TJ, Mclntyre BW, Clayberger C, et al. Novel tumor-associated accessory molecules involved in the gamma/delta cytotoxic T-lymphocyte-Burkitt’s lymphoma interaction. Cancer. 1995;75:886–93. [DOI] [PubMed]

69.

Uchida R, Ashihara E, Sato K, Kimura S, Kuroda J, Takeuchi M, et al. Gamma delta T cells kill myeloma cells by sensing mevalonate metabolites and ICAM-1 molecules on cell surface. Biochem Biophys Res Commun. 2007;354:613–8. [DOI] [PubMed]

70.

Liu Z, Guo B, Lopez RD. Expression of intercellular adhesion molecule (ICAM)-1 or ICAM-2 is critical in determining sensitivity of pancreatic cancer cells to cytolysis by human gammadelta-T cells: implications in the design of gammadelta-T-cell-based immunotherapies for pancreatic cancer. J Gastroenterol Hepatol. 2009;24:900–11. [DOI] [PubMed]

71.

Weng RR, Lu HH, Lin CT, Fan CC, Lin RS, Huang TC, et al. Epigenetic modulation of immune synaptic-cytoskeletal networks potentiates γδ T cell-mediated cytotoxicity in lung cancer. Nat Commun. 2021;12:2163. [DOI] [PubMed] [PMC]

72.

Thomas ML, Badwe RA, Deshpande RK, Samant UC, Chiplunkar SV. Role of adhesion molecules in recruitment of Vdelta1 T cells from the peripheral blood to the tumor tissue of esophageal cancer patients. Cancer Immunol Immunother. 2001;50:218–25. [DOI] [PubMed]

73.

Byeseda SE, Burns AR, Dieffenbaugher S, Rumbaut RE, Smith CW, Li Z. ICAM-1 is necessary for epithelial recruitment of gammadelta T cells and efficient corneal wound healing. Am J Pathol. 2009;175:571–9. [DOI] [PubMed] [PMC]

74.

Johnson MD, Otuki MF, Cabrini DA, Rudolph R, Witherden DA, Havran WL. Hspa8 and ICAM-1 as damage-induced mediators of γδ T cell activation. J Leukoc Biol. 2022;111:135–45. [DOI] [PubMed]

75.

Nagaoka T, Kaburagi Y, Hamaguchi Y, Hasegawa M, Takehara K, Steeber DA, et al. Delayed wound healing in the absence of intercellular adhesion molecule-1 or L-selectin expression. Am J Pathol. 2000;157:237–47. [DOI] [PubMed] [PMC]

76.

Sumagin R, Brazil JC, Nava P, Nishio H, Alam A, Luissint AC, et al. Neutrophil interactions with epithelial-expressed ICAM-1 enhances intestinal mucosal wound healing. Mucosal Immunol. 2016;9:1151–62. [DOI] [PubMed] [PMC]

77.

Stipp CS, Kolesnikova TV, Hemler ME. EWI-2 is a major CD9 and CD81 partner and member of a novel Ig protein subfamily. J Biol Chem. 2001;276:40545–54. [DOI] [PubMed]

78.

Gordón-Alonso M, Sala-Valdés M, Rocha-Perugini V, Pérez-Hernández D, López-Martín S, Ursa A, et al. EWI-2 association with α-actinin regulates T cell immune synapses and HIV viral infection. J Immunol. 2012;189:689–700. [DOI] [PubMed]

79.

Kettner S, Kalthoff F, Graf P, Priller E, Kricek F, Lindley I, et al. EWI-2/CD316 is an inducible receptor of HSPA8 on human dendritic cells. Mol Cell Biol. 2007;27:7718–26. [DOI] [PubMed] [PMC]

80.

Hirsh MI, Junger WG. Roles of heat shock proteins and gamma delta T cells in inflammation. Am J Respir Cell Mol Biol. 2008;39:509–13. [DOI] [PubMed] [PMC]

81.

Wu J, Liu T, Rios Z, Mei Q, Lin X, Cao S. Heat shock proteins and cancer. Trends Pharmacol Sci. 2017;38:226–56. [DOI] [PubMed]

82.

Chatterjee S, Burns TF. Targeting heat shock proteins in cancer: a promising therapeutic approach. Int J Mol Sci. 2017;18:1978. [DOI] [PubMed] [PMC]

83.

Ren F, Xu Y, Mao L, Ou R, Ding Z, Zhang X, et al. Heat shock protein 110 improves the antitumor effects of the cytotoxic T lymphocyte epitope E7(49-57) in mice. Cancer Biol Ther. 2010;9:134–41. [DOI] [PubMed]

84.

Manjili MH, Park JE, Facciponte JG, Wang XY, Subjeck JR. Immunoadjuvant chaperone, GRP170, induces ‘danger signals’ upon interaction with dendritic cells. Immunol Cell Biol. 2006;84:203–8. [DOI] [PubMed] [PMC]

85.

Shevtsov M, Multhoff G. Heat shock protein-peptide and HSP-based immunotherapies for the treatment of cancer. Front Immunol. 2016;7:171. [DOI] [PubMed] [PMC]

86.

O’Brien RL, Born W. Heat shock proteins as antigens for gamma delta T cells. Semin Immunol. 1991;3:81–7. [PubMed]

87.

Laad AD, Thomas ML, Fakih AR, Chiplunkar SV. Human gamma delta T cells recognize heat shock protein-60 on oral tumor cells. Int J Cancer. 1999;80:709–14. [DOI] [PubMed]

88.

Zhang H, Hu H, Jiang X, He H, Cui L, He W. Membrane HSP70: the molecule triggering γδ T cells in the early stage of tumorigenesis. Immunol Invest. 2005;34:453–68. [DOI] [PubMed]

89.

Fu YX, Cranfill R, Vollmer M, Van Der Zee R, O’Brien RL, Born W. In vivo response of murine gamma delta T cells to a heat shock protein-derived peptide. Proc Natl Acad Sci U S A. 1993;90:322–6. [DOI] [PubMed] [PMC]

90.

Tsuji M, Mombaerts P, Lefrancois L, Nussenzweig RS, Zavala F, Tonegawa S. Gamma delta T cells contribute to immunity against the liver stages of malaria in alpha beta T-cell-deficient mice. Proc Natl Acad Sci U S A. 1994;91:345–9. [DOI] [PubMed] [PMC]

91.

Beagley KW, Fujihashi K, Black CA, Lagoo AS, Yamamoto M, McGhee JR, et al. The Mycobacterium tuberculosis 71-kDa heat-shock protein induces proliferation and cytokine secretion by murine gut intraepithelial lymphocytes. Eur J Immunol. 1993;23:2049–52. [DOI] [PubMed]

92.

Egan PJ, Carding SR. Downmodulation of the inflammatory response to bacterial infection by gammadelta T cells cytotoxic for activated macrophages. J Exp Med. 2000;191:2145–58. [DOI] [PubMed] [PMC]

93.

Belles C, Kuhl A, Nosheny R, Carding SR. Plasma membrane expression of heat shock protein 60 in vivo in response to infection. Infect Immun. 1999;67:4191–200. [DOI] [PubMed] [PMC]

94.

Habich C, Kempe K, van der Zee R, Rümenapf R, Akiyama H, Kolb H, et al. Heat shock protein 60: specific binding of lipopolysaccharide. J Immunol. 2005;174:1298–305. [DOI] [PubMed]

95.

Bausinger H, Lipsker D, Ziylan U, Manié S, Briand JP, Cazenave JP, et al. Endotoxin-free heat-shock protein 70 fails to induce APC activation. Eur J Immunol. 2002;32:3708–13. [DOI] [PubMed]

96.

Miyashita M, Shimizu T, Ashihara E, Ukimura O. Strategies to improve the antitumor effect of γδ T cell immunotherapy for clinical application. Int J Mol Sci. 2021;22:8910. [DOI] [PubMed] [PMC]

97.

Rigau M, Uldrich AP, Behren A. Targeting butyrophilins for cancer immunotherapy. Trends Immunol. 2021;42:670–80. [DOI] [PubMed]

98.

Uldrich AP, Rigau M, Godfrey DI. Immune recognition of phosphoantigen-butyrophilin molecular complexes by γδ T cells. Immunol Rev. 2020;298:74–83. [DOI] [PubMed]

99.

Ribot JC, Lopes N, Silva-Santos B. γδ T cells in tissue physiology and surveillance. Nat Rev Immunol. 2021;21:221–32. [DOI] [PubMed]

100.

Vantourout P, Laing A, Woodward MJ, Zlatareva I, Apolonia L, Jones AW, et al. Heteromeric interactions regulate butyrophilin (BTN) and BTN-like molecules governing γδ T cell biology. Proc Natl Acad Sci U S A. 2018;115:1039–44. [DOI] [PubMed] [PMC]

101.

Hayday AC. γδ T cell update: adaptate orchestrators of immune surveillance. J Immunol. 2019;203:311–20. [DOI] [PubMed]

102.

Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood. 2000;96:384–92. [DOI] [PubMed]

103.

Yazdanifar M, Barbarito G, Bertaina A, Airoldi I. γδ T cells: the ideal tool for cancer immunotherapy. Cells. 2020;9:1305. [DOI] [PubMed] [PMC]

104.

Fisher JP, Heuijerjans J, Yan M, Gustafsson K, Anderson J. γδ T cells for cancer immunotherapy: a systematic review of clinical trials. Oncoimmunology. 2014;3:e27572. [DOI] [PubMed] [PMC]

105.

Kouakanou L, Xu Y, Peters C, He J, Wu Y, Yin Z, et al. Vitamin C promotes the proliferation and effector functions of human γδ T cells. Cell Mol Immunol. 2020;17:462–73. [DOI] [PubMed] [PMC]

106.

Payne KK, Mine JA, Biswas S, Chaurio RA, Perales-Puchalt A, Anadon CM, et al. BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells. Science. 2020;369:942–9. [DOI] [PubMed] [PMC]

107.

De Gassart A, Le KS, Brune P, Agaugué S, Sims J, Goubard A, et al. Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell-mediated antitumor immune response. Sci Transl Med. 2021;13:eabj0835. [DOI] [PubMed]

108.

Schilbach K, Krickeberg N, Kaiβer C, Mingram S, Kind J, Siegers GM, et al. Suppressive activity of Vδ2⁺ γδ T cells on αβ T cells is licensed by TCR signaling and correlates with signal strength. Cancer Immunol Immunother. 2020;69:593–610. [DOI] [PubMed] [PMC]

109.

Traxlmayr MW, Wesch D, Dohnal AM, Funovics P, Fischer MB, Kabelitz D, et al. Immune suppression by gammadelta T-cells as a potential regulatory mechanism after cancer vaccination with IL-12 secreting dendritic cells. J Immunother. 2010;33:40–52. [DOI] [PubMed]

110.

Casetti R, Agrati C, Wallace M, Sacchi A, Martini F, Martino A, et al. Cutting edge: TGF-β1 and IL-15 induce FOXP3⁺ γδ regulatory T cells in the presence of antigen stimulation. J Immunol. 2009;183:3574–7. [DOI] [PubMed]

111.

Peters C, Kabelitz D, Wesch D. Regulatory functions of γδ T cells. Cell Mol Life Sci. 2018;75:2125–35. [DOI] [PubMed]

112.

Almeida AR, Correia DV, Fernandes-Platzgummer A, da Silva CL, da Silva MG, Anjos DR, et al. Delta one T cells for immunotherapy of chronic lymphocytic leukemia: clinical-grade expansion/differentiation and preclinical proof of concept. Clin Cancer Res. 2016;22:5795–804. [DOI] [PubMed]

113.

Di Lorenzo B, Simões AE, Caiado F, Tieppo P, Correia DV, Carvalho T, et al. Broad cytotoxic targeting of acute myeloid leukemia by polyclonal delta one T cells. Cancer Immunol Res. 2019;7:552–8. [DOI] [PubMed]

114.

Rozenbaum M, Meir A, Aharony Y, Itzhaki O, Schachter J, Bank I, et al. Gamma-delta CAR-T cells show CAR-directed and independent activity against leukemia. Front Immunol. 2020;11:1347. [DOI] [PubMed] [PMC]

115.

Fisher J, Sharma R, Don DW, Barisa M, Hurtado MO, Abramowski P, et al. Engineering γδT cells limits tonic signaling associated with chimeric antigen receptors. Sci Signal. 2019;12:eaax1872. [DOI] [PubMed] [PMC]

116.

Mirzaei HR, Mirzaei H, Lee SY, Hadjati J, Till BG. Prospects for chimeric antigen receptor (CAR) γδ T cells: a potential game changer for adoptive T cell cancer immunotherapy. Cancer Lett. 2016;380:413–23. [DOI] [PubMed] [PMC]

117.

Oberg HH, Peipp M, Kellner C, Sebens S, Krause S, Petrick D, et al. Novel bispecific antibodies increase γδ T-cell cytotoxicity against pancreatic cancer cells. Cancer Res. 2014;74:1349–60. [DOI] [PubMed]

118.

Oberg HH, Kellner C, Gonnermann D, Peipp M, Peters C, Sebens S, et al. γδ T cell activation by bispecific antibodies. Cell Immunol. 2015;296:41–9. [DOI] [PubMed]

119.

Ganesan R, Chennupati V, Ramachandran B, Hansen MR, Singh S, Grewal IS. Selective recruitment of γδ T cells by a bispecific antibody for the treatment of acute myeloid leukemia. Leukemia. 2021;35:2274–84. [DOI] [PubMed] [PMC]

120.

Mayes PA, Hance KW, Hoos A. The promise and challenges of immune agonist antibody development in cancer. Nat Rev Drug Discov. 2018;17:509–27. [DOI] [PubMed]

121.

Thommen DS, Schumacher TN. T cell dysfunction in cancer. Cancer Cell. 2018;33:547–62. [DOI] [PubMed] [PMC]

122.

Ceglia V, Zurawski S, Montes M, Bouteau A, Wang Z, Ellis J, et al. Anti-CD40 antibodies fused to CD40 ligand have superagonist properties. J Immunol. 2021;207:2060–76. [DOI] [PubMed] [PMC]

123.

Zhang D, Goldberg MV, Chiu ML. Fc engineering approaches to enhance the agonism and effector functions of an anti-OX40 antibody. J Biol Chem. 2016;291:27134–46. [DOI] [PubMed] [PMC]

124.

Shafique MR, Fisher TL, Evans EE, Leonard JE, Pastore DRE, Mallow CL, et al. A phase Ib/II study of pepinemab in combination with avelumab in advanced non-small cell lung cancer. Clin Cancer Res. 2021;27:3630–40. [DOI] [PubMed]

125.

Rossi AJ, Khan TM, Hong H, Lesinski GB, Wu C, Hernandez JM. Pepinemab (anti-SEMA4D) in combination with ipilimumab or nivolumab for patients with resectable pancreatic and colorectal cancer. Ann Surg Oncol. 2021;28:4098–9. [DOI] [PubMed]

126.

Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human gammadelta T cells. Science. 2005;309:264–8. [DOI] [PubMed]

127.

Brandes M, Willimann K, Bioley G, Lévy N, Eberl M, Luo M, et al. Cross-presenting human gammadelta T cells induce robust CD8⁺ alphabeta T cell responses. Proc Natl Acad Sci U S A. 2009;106:2307–12. [DOI] [PubMed] [PMC]

128.

Meuter S, Eberl M, Moser B. Prolonged antigen survival and cytosolic export in cross-presenting human gammadelta T cells. Proc Natl Acad Sci U S A. 2010;107:8730–5. [DOI] [PubMed] [PMC]

129.

Holmen Olofsson G, Idorn M, Carnaz Simões AM, Aehnlich P, Skadborg SK, Noessner E, et al. Vγ9Vδ2 T cells concurrently kill cancer cells and cross-present tumor antigens. Front Immunol. 2021;12:645131. [DOI] [PubMed] [PMC]

130.

Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21:145–61. [DOI] [PubMed] [PMC]

131.

Riddell SR, Greenberg PD. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods. 1990;128:189–201. [DOI] [PubMed]

132.

Testi R, Lanier LL. Functional expression of CD28 on T cell antigen receptor gamma/delta-bearing T lymphocytes. Eur J Immunol. 1989;19:185–8. [DOI] [PubMed]

133.

Ribot JC, Debarros A, Mancio-Silva L, Pamplona A, Silva-Santos B. B7-CD28 costimulatory signals control the survival and proliferation of murine and human γδ T cells via IL-2 production. J Immunol. 2012;189:1202–8. [DOI] [PubMed]

134.

Berglund S, Gaballa A, Sawaisorn P, Sundberg B, Uhlin M. Expansion of gammadelta T cells from cord blood: a therapeutical possibility. Stem Cells Int. 2018;2018:8529104. [DOI] [PubMed] [PMC]

135.

Lafont V, Liautard J, Gross A, Liautard JP, Favero J. Tumor necrosis factor-alpha production is differently regulated in gamma delta and alpha beta human T lymphocytes. J Biol Chem. 2000;275:19282–7. [DOI] [PubMed]

136.

Phung SK, Miller JS, Felices M. Bi-specific and tri-specific NK cell engagers: the new avenue of targeted NK cell immunotherapy. Mol Diagn Ther. 2021;25:577–92. [DOI] [PubMed]